Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn’s Surgical Patients
BACKGROUND:
There is no study to date examining the safety of initiating or restarting biologic therapy after major abdominal surgery for Crohn’s disease.
OBJECTIVE:
The purpose of this study was to determine differences in the rates of 90-day superficial surgical site infections, intra-abdominal sepsis, and overall postoperative infectious complications among patients who were initiated on or restarted a biologic within 90 days postoperatively compared with those who were not.
DESIGN:
This was a retrospective cohort study.
SETTINGS:
The study was conducted at an IBD referral center.
PATIENTS:
Adult patients with Crohn’s disease who received a biologic therapy within 90 days of a major abdominal operation between May 20, 2014, and December 31, 2018, were included.
MAIN OUTCOMES MEASURES:
Ninety-day superficial surgical site infection, intra-abdominal sepsis, and overall postoperative infectious complications were measured.
RESULTS:
A total of 680 patients with Crohn’s disease were included: 351 were initiated on biologic therapy within 90 days after surgery and 329 were not. Patients exposed to biologic therapy postoperatively were younger (p
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions: Inflammatory Bowel Disease Source Type: research